Form 4: Quest Diagnostics Director, Tracey Doi, Reports Acquisition of Restricted Stock Units
SEC Form 4 Filing
Tracey Doi, a director at Quest Diagnostics, reported the acquisition of 1,203 restricted stock units on May 15, 2025.
Summary
- Tracey Doi, a director of Quest Diagnostics Inc. (DGX), filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on May 15, 2025.
- Doi acquired 1,203 shares of common stock in the form of restricted stock units.
- Following the transaction, Doi beneficially owns 6,490 shares of Quest Diagnostics common stock.
- The acquisition was a direct transaction.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Form 4) detailing a director's acquisition of restricted stock units. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in company stock. This filing indicates a director's acquisition of restricted stock units, which is a common form of executive compensation.
Stakeholder Impact
- The acquisition of restricted stock units by a director aligns their interests with those of shareholders, potentially incentivizing them to work towards the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of transaction: Acquisition of restricted stock units. |
| 05/19/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Quest Diagnostics, DGX, Insider Trading, Tracey Doi, Restricted Stock Units, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.